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Abstract
Background: Medication nonadherence costs $300 billion annually in the US. Medicare Advantage plans have a
financial  incentive  to  increase  medication  adherence  among  members  because  the  Centers  for  Medicare  and
Medicaid  Services  (CMS)  now  awards  substantive  bonus  payments  to  such  plans,  based  in  part  on  population
adherence to chronic medications. We sought to build an individualized surveillance model that detects early which
beneficiaries will fall below the CMS adherence threshold.
Methods: This was a retrospective study of over 210,000 beneficiaries initiating statins, in a database of private
insurance  claims,  from  2008-2011.  A  logistic  regression  model  was  constructed  to  use  statin  adherence  from
initiation to day 90 to predict beneficiaries who would not meet the CMS measure of proportion of days covered 0.8
or above, from day 91 to 365. The model controlled for 15 additional characteristics. In a sensitivity analysis, we
varied the number of days of adherence data used for prediction.
Results: Lower adherence in the first 90 days was the strongest predictor of one-year nonadherence, with an odds
ratio of 25.0 (95% confidence interval 23.7-26.5) for poor adherence at one year. The model had an area under the
receiver operating characteristic curve of 0.80. Sensitivity analysis revealed that predictions of comparable accuracy
could be made only 40 days after statin initiation. When members with 30-day supplies for their first statin fill had
predictions made at 40 days, and members with 90-day supplies for their first fill had predictions made at 100 days,
poor adherence could be predicted with 86% positive predictive value.
Conclusions: To preserve their Medicare Star ratings, plan managers should identify or develop effective programs
to improve adherence. An individualized surveillance approach can be used to target members who would most
benefit,  recognizing  the  tradeoff  between  improved  model  performance  over  time  and  the  advantage  of  earlier
detection.
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Introduction
Poor  medication  adherence  costs  the  U.S.  healthcare
system up to nearly $300 billion[1-3] each year. Patients who
adhere  to  prescribed  medication  have  fewer  hospitalizations,
lower  costs[4],  and  lower  mortality[5],  as  compared  to  their
non-adherent  counterparts.  Nonadherence  is  common;  in
studies  of  statin  adherence,  only  around  50%  of  subjects
remain  fully  adherent  6  months  after  initiation[6,7].  However,
interventions to improve adherence are often cost- and time-
intensive[8,9].
In 2012, as required by the Patient Protection and Affordable
Care  Act,  the  Centers  for  Medicare  and  Medicaid  Services
(CMS)  began  using  star  ratings  to  award  substantive  bonus
payments  to  privately-run  Medicare  Advantage  and  stand-
alone  Medicare  prescription  drug  plans[8,10,11].  Higher  star
ratings are also associated with higher plan enrollment[12]. An
important  component  of  assigning  these  ratings  is  the
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e79611proportion  of  plan  beneficiaries  who  achieve  a  proportion  of
days covered (PDC) of 0.8 or above[11], for three classes of
medications: statins, renin angiotensin system antagonists, and
oral hypoglycemic agents. The adherence measures for these
classes are obtained from prescription fulfillment data and are
measured  over  a  one-year  period.  We  sought  to  develop  a
predictive  model  of  poor  adherence  to  statins  so  that  plan
managers,  early  in  the  year,  can  efficiently  implement  and
target programs to the right patients.
Methods
Design
This was a retrospective database study using de-identified
medical  and  pharmacy  claims,  on  all  Aetna  commercial
members  with  at  least  one  year  of  continuous  medical  and
pharmacy coverage from 2008-2011. Patients were included if
they  received  a  statin  prescription  and  met  criteria  for
dyslipidemia, where dyslipidemia was defined as: 2 claims with
a  diagnosis  of  lipid  disorder  (International  Classification  of
Diseases,  Ninth  Revision  (ICD-9)  diagnosis  code  of  272.x)
unrelated  to  a  laboratory  claim,  or  low-density  lipoprotein
cholesterol  >130  mg/dL  (to  convert  to  millimoles  per  liter,
multiply by 0.0259), or total cholesterol >200 mg/dL, or HDL
cholesterol <40 mg/dL, or triglycerides >150 mg/dL (to convert
to  millimoles  per  liter,  multiply  by  0.0113),  or  a  claim  with  a
Current  Procedural  Terminology  Category  II  code  for  a  lipid
disorder (3049F, 3050F, 4013F, 0556F, or 4002F). Raw data
are available upon request.
Members  with  unknown  gender  or  with  ages  <0  or  >100
years were excluded, as were members who received high fill
quantities (>100 days) likely to be in error or not reflective of
true  days  covered.  The  members  (<0.1%  of  total)  taking
lovastatin were excluded from final analysis because this very
low  prevalence  category  destabilized  the  model.  Members
were  excluded  if  they  had  less  than  90  days  of  continuous
eligibility after statin initiation. Finally, to provide a “wash out”
period  that  would  separate  those  truly  initiating  statins  from
those merely continuing statins after switching plans, members
were  excluded  if  the  time  from  first  eligibility  to  first  statin
prescription  was  less  than  180  days.  The  data  were  divided
into training and validation subsets (two thirds and one third of
members, respectively).
Ethics statement
The study was reviewed and approved by the Committee on
Human  Studies  of  Harvard  Medical  School.  Consent  was
waived  by  the  Committee,  which  identified  the  study  as  not
involving human subjects per Federal regulations.
Adherence measurement
For  each  member,  we  calculated  PDC  for  days  91-365
(PDC91-365), dichotomized at the 0.8 level, to be used as the
outcome  variable.  This  measure  calculates  adherence  in  a
period  that  does  not  overlap  with  the  early  detection  period.
Day 1 (index date) is defined as the fill date for the first statin
prescription  for  that  member.  All  PDC  calculations  were
performed  according  to  methods  described  by  CMS.[11]
Specifically, PDC was defined as the number of days that the
member  was  covered  by  at  least  one  statin,  divided  by  the
number of days in the measurement period. PDC over 100%
(when the member fills more than expected) is expressed as
100%. Days of overlap between two fills counted toward PDC,
but only if the two fills were for the same statin. If prescriptions
in days 1-90 had days of supply that extended into the days
91-365  period,  those  days  of  supply  contributed  toward
PDC91-365.  The  days  covered  and  the  duration  of  the
measurement  period  were  adjusted  for  inpatient  stays
according  to  the  CMS  methods  (“drug  coverage  during  the
inpatient stay is shifted to subsequent days of no supply,” and
“the days of inpatient stay are deleted from the measurement
period”)[11]. For members with less than one year of eligibility
after the index date, PDC91-365 could not be calculated.
Baseline variables used to predict adherence
The primary independent measure was PDC for days 1-90,
analyzed as a continuous variable (PDC1-90). Model building
was  similar  to  a  prior  analysis,  on  a  different  population,
predicting medication possession ratio[13]. We considered 15
additional variables focusing on those previously shown to be
associated  with  adherence[1,6,7,14].  Age,  gender,  and  statin
name  were  available  from  claims  data.  For  statin  name,
simvastatin  was  designated  as  the  comparator  for  all  other
categories. We calculated the following variables from the first
90 days only after the index date (Figure 1): proportion of statin
fills  at  retail  pharmacies,  proportion  of  formulary  statin  fills,
proportion of generic statin fills, average days supply per statin
prescription,  average  statin  reimbursement  per  prescription,
average statin copayment per prescription, and average statin
dose  per  prescription.  Finally,  we  calculated  the  following
variables  to  describe  the  period  from  the  first  non-statin
prescription to the index date (Figure 1): average pills per day,
average non-statin reimbursement per day, average non-statin
copayment  per  day,  presence  of  acute  coronary  syndrome
within 30 days prior to index date (defined as hospitalization for
unstable angina or myocardial infarction, ICD-9 codes 411.x or
410.x), and time from first eligibility to index date.
Analyses
Using  logistic  regression,  bivariate  associations  were
explored  between  baseline  variables  and  PDC91-365
(dichotomized at 0.8). For continuous baseline variables, units
for the odds ratios were set equal to 2 standard deviations of
the  variable.  This  method  allows  comparison  of  continuous
variables’ impact on model discrimination[15]. A multivariable
logistic  regression  model  was  developed  on  the  training  set,
using continuous PDC1-90 and the 15 additional variables to
predict  probability  of  poor  adherence  (PDC91-365
dichotomized at 0.8). All baseline variables were included, and
no further selection of variables was performed.
The trained model was applied to the validation set, and a
receiver  operating  characteristic  (ROC)  curve  was  plotted.
Odds ratios with 95% confidence intervals were determined for
each  variable.  For  continuous  variables,  units  for  the  odds
ratios were set equal to 2 standard deviations of the variable.
Adherence Surveillance for Pay-for-Performance
PLOS ONE | www.plosone.org 2 November 2013 | Volume 8 | Issue 11 | e79611We applied the model to all beneficiaries in the validation set.
However,  those  who  left  the  plan  before  year’s  end  had
censored  data.  For  those  with  censored  data,  model
predictions  can  be  made  but  not  classified  as  true  or  false;
therefore  members  with  censored  data  do  not  contribute  to
sensitivity  and  specificity  calculations.  However,  we  report
numbers  of  members  with  censored  data  because,  from  the
plan  manager’s  perspective,  resources  would  be  devoted
toward  those  at  risk  for  nonadherence,  and  it  would  not  be
known in advance which members would leave the plan before
one year.
Our primary multivariable model requires 90 days of data to
predict future nonadherence, but in practice an insurance plan
manager may be willing to sacrifice model performance for a
prediction  sooner  than  90  days.  Thus,  we  performed  a
sensitivity analysis, varying the date of prediction from 0 to 270
days, and examining impact on prediction AUC. We stratified
this analysis by the days’ supply of the first statin fill (≤30 days
versus  >30  days).  We  inspected  the  performance  vs.  time
curves  for  both  subsets  and  also  calculated  performance
characteristics  that  would  result  if  predictions  were  made  at
different  time  points  for  the  two  subsets  (as  opposed  to  our
single  90-day  time  point  used  in  the  primary  model).  All
analyses  were  performed  using  SAS  statistical  software,
version 9.3 (SAS Institute Inc, Cary, NC).
Results
A  total  of  624,781  members  met  inclusion  criteria.  After
exclusion criteria were applied, 217,928 remained (Figure 2).
Table 1 shows baseline characteristics of the members.
Table 2 shows the pairwise associations between baseline
variables and PDC91-365. Early PDC had the strongest effect
of  all  variables  (odds  ratio  for  poor  adherence  19.9  per  2
standard  deviation  decrease  in  early  PDC,  95%  confidence
interval 19.0-20.9).
In multivariable analysis, the model had an AUC of 0.80 for
the training set and validation set both. Adjusted odds ratios
and  95%  confidence  intervals  for  all  variables  are  shown  in
Table 2. Early PDC had the strongest effect of all variables in
the model. Specifically, patients with a lower PDC at 90 days
had an odds ratio of 25.0 (95% confidence interval 23.7-26.5)
for poor adherence from days 91 to 365. The positive predictive
value  for  poor  adherence  is  87.7%,  and  negative  predictive
value is 53.4%. The model can predict the CMS definition of
statin  nonadherence  with  69.5%  sensitivity  and  78.2%
specificity.  For  every  1000  beneficiaries,  the  model  predicts
poor adherence for 562. Of those, 335 are true positives, 47
are false positives and 180 are censored (eligibility ends within
a year of statin initiation). The model predicts good adherence
for 438 beneficiaries, of whom 168 are true negatives, 147 are
false negatives, and 123 are censored.
Figure 1.  Timeline showing periods used to calculate adherence measures and baseline variables.  Outcome variable is
proportion of days covered (PDC) by statin for days 91-365, respectively. Three baseline variables are calculated from the first non-
statin prescription to the index date. Presence of ACS (acute coronary syndrome) as a baseline variable was determined in the 30
days prior to statin initiation. Nine baseline variables including early PDC are calculated from statin prescriptions in days 1-90. Time
from eligibility to initiation is required to be 180 days (in both models) in order to include those truly initiating statins, and not those
merely continuing statins after switching insurance plans.
doi: 10.1371/journal.pone.0079611.g001
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were  based  on  less  than  30  days  of  early  adherence
monitoring  (AUCs  near  0.6).  Model  performance  increases
sharply from days 30 to 31 (from AUC 0.62 to 0.71) for those
members whose first prescription was for a 30-day supply or
less, and it improved steadily thereafter. For those members
whose first prescription was for more than 30 days, (most of
whom  received  90-day  supplies,)  AUC  did  not  increase  until
after day 90 (Figure 3). When members with 30-day supplies
for their first statin fill had predictions made at 40 days, and
members with 90-day supplies for their first fill had predictions
made  at  100  days,  poor  adherence  could  be  predicted  with
86% positive predictive value, 50% negative predictive value,
69% sensitivity, and 74% specificity.
Discussion
Early PDC is a strong indicator of future nonadherence, and,
in  fact  stronger  than  variables  identified  in  prior  studies[8]
which have shown relatively low predictive power of insurance
claims,  with  AUCs  under  0.64[14].  We  show,  however,  that
while  claims  data  have  limited  value  prior  to  initiation  of  the
medication,  they  contain  important  information  after  several
weeks  of  filling  behavior,  as  they  become  an  indicator  of
personal behavior[16].
Because  CMS  now  uses  adherence  to  award  bonus
payments,  adherence  is  tied  to  direct  financial  incentives  as
well as incentives to prevent morbidity and mortality. We show
that the CMS metric of PDC can be predicted far in advance;
therefore  plan  managers  could  apply  an  individualized
surveillance model to target adherence improvement programs
to  their  Medicare  Advantage  members  who  are  at  risk  for
nonadherence  and  who  are  likely  to  benefit  from  such
programs.
Prediction of PDC improves with time. Our primary model,
which  uses  90  days  of  adherence  data,  performs  well,  but
sensitivity analysis demonstrates the utility of early monitoring
as early as day 31. Little improvement in model performance is
gained from monitoring adherence before the first prescription
fill is expected to run out. A plan manager can account for the
tradeoff  between  early  detection  of  poor  adherers  and
accuracy,  based  on  the  cost  and  characteristics  of  the
intervention.
A limitation of this study, in common with much claims-based
adherence research, and in fact with the very PDC metric used
by CMS, is that it treats medication fills as essentially the same
as adherence, which is a simplified conception[8]. Our model
does not address self-report, pill counts, or other measures of
adherence, and further research should use these measures
as outcome variables, either singly or in combination. Similarly,
all  purely  claims-based  adherence  research,  including  this
study,  cannot  address  underlying  reasons  for  treatment
discontinuations,  including  discontinuations  that  are
recommended  by  the  prescriber.  Adherence  is  commonly
defined as “the extent to which patients take medications as
prescribed by their health care providers,”[1] and this cannot
strictly  be  assessed  with  prescription  claims  data  alone.
Second, there is only slim evidence that the 0.8 PDC threshold
is  clinically  meaningful[8,17].  Third,  it  may  be  difficult  to
separate  any  true  effect  of  90-day  prescription  supplies  on
adherence  from  the  effect  of  days  supply  on  the  PDC
Figure 2.  Study flow diagram showing exclusion criteria.  The sum of members who met each individual exclusion criterion
does not equal the total number excluded because one member can meet more than one exclusion criterion.
doi: 10.1371/journal.pone.0079611.g002
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the effect of days supply on pill taking, not just on metrics of
prescription filling. Finally, our source population is commercial
insurance  members  who  were  initiating  statins;  we  did  not
study  the  Medicare  population  or  those  who  were  already
taking  statins  when  they  entered  our  dataset.  These
populations are important for the proposed application of our
model,  and  its  performance  should  be  confirmed  in  these
populations.
To  further  increase  accuracy  of  detection,  the  use  of
additional  data  sources,  including  electronic  medical  record
information  and  patient-reported  adherence,  should  be
explored.
Table 1. Baseline characteristics of the study population before and after exclusion criteriaa.
Characteristic All members (n = 624781) Selected cohort (n = 217928)
Age, median (IQR), y 56 (49-62) 54 (47-61)
Sex    
Women 264541 (42.3) 98840 (45.4)
Men 360237 (57.7) 119088 (54.6)
PDC, days 1-90, median (IQR) 0.96 (0.67-1.00) 0.87 (0.59-1.00)
PDC, days 1-365, median (IQR) 0.76 (0.41-0.95) 0.58 (0.25-0.89)
< 0.8 268457 (43.0) 100879 (46.3)
≥ 0.8 240277 (38.5) 51223 (23.5)
Unknown (censored) 116047 (18.6) 65826 (30.2)
PDC, days 91-365, median (IQR) 0.73 (0.33-0.94) 0.51 (0.11-0.87)
< 0.8 285008 (45.6) 104750 (48.1)
≥ 0.8 223726 (35.8) 47352 (21.7)
Unknown (censored) 116047 (18.6) 65826 (30.2)
Medication    
Simvastatin 318408 (51.0) 126464 (58.0)
Atorvastatin 159434 (25.5) 33777 (15.5)
Rosuvastatin 127800 (20.5) 52466 (24.1)
Fluvastatin 6528 (1.0) 700 (0.3)
Pravastatin 1176 (0.2) 323 (0.1)
Lovastatin 48 (0.0) 0
Multiple 11387 (1.8) 4198 (1.9)
Source of majority of statins, days 1-90    
Mail order 122852 (19.7) 24669 (11.3)
Retail 501929 (80.3) 193259 (88.7)
Formulary status of majority of statins, days 1-90    
Formulary 457886 (73.3) 182061 (83.5)
Nonformulary 166895 (26.7) 35867 (16.5)
Generic status of majority of statins, days 1-90    
Generic 319374 (51.1) 127235 (58.4)
Brand-name 305407 (48.9) 90693 (41.6)
ACS in 30 days prior to statin initiation 6674 (1.1) 4340 (2.0)
Average supply per statin fill, days 1-90, median (IQR), days 30 (30-60) 30 (30-30)
First fill ≤ 30 d 468354 (75.0) 182989 (84.0)
First fill > 30 d 156427 (25.0) 34939 (16.0)
Average statin payment, days 1-90, median (IQR), $ 47.21 (3.08-94.50) 11.73 (2.35-85.14)
Average statin copayment, days 1-90, median (IQR), $ 20 (10-40) 15 (10-30)
Average statin dose, days 1-90, median (IQR), mg 20 (10-40) 20 (10-40)
Time from eligibility to statin initiation, median (IQR), days 82 (14-355) 446 (295-679)
Time from statin initiation to end of eligibility, median (IQR), days 734 (443-1129) 541 (317-820)
Pills per day, first prescription ever to statin initiation, median (IQR) 0.00 (0.00-1.26) 0.40 (0.00-1.83)
Payment per day, first prescription ever to statin initiation, median (IQR), $ 0.00 (0.00-1.49) 0.16 (0.00-2.17)
Copayment per day, first prescription ever to statin initiation, median (IQR), $ 0.00 (0.00-0.98) 0.25 (0.00-1.03)
aValues are presented as number (percentage) unless otherwise indicated. Abbreviations: ACS, acute coronary syndrome; IQR, interquartile range; PDC, proportion of days
covered.
doi: 10.1371/journal.pone.0079611.t001
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Variable Odds ratio (95% CI) P value Adjusted odds ratio (95% CI) P value
PDC days 1-90 0.04 (0.04-0.05) <.001 0.04 (0.04-0.04) <.001
Age 0.54 (0.53-0.55) <.001 0.64 (0.62-0.66) <.001
Mail order source of majority of statins, days 1-90 0.42 (0.40-0.44) <.001 0.67 (0.63-0.71) <.001
Pills per day, prior to statin initiation 0.64 (0.62-0.66) <.001 0.78 (0.75-0.81) <.001
Brand-name status of majority of statins, days 1-90 1.08 (1.05-1.11) <.001 0.86 (0.69-1.05) 0.140
Average reimbursed amount per day, prior to statin initiation 0.71 (0.69-0.74) <.001 0.97 (0.93-1.00) 0.088
Average copayment per day, prior to statin initiation 0.75 (0.71-0.79) <.001 0.98 (0.96-1.01) 0.265
Average statin dose, first 90 days of statin era 0.97 (0.95-1.00) 0.020 1.09 (1.06-1.13) <.001
Days from eligibility to statin initiation 1.05 (1.02-1.08) 0.004 1.10 (1.06-1.14) <.001
Average reimbursed amount, first 90 days of statin era 0.71 (0.69-0.73) <.001 1.10 (1.04-1.16) 0.001
Nonformulary status of majority of statins, days 1-90 1.09 (1.06-1.13) <.001 1.09 (0.94-1.27) 0.238
Average copayment, first 90 days of statin era 0.97 (0.94-0.99) 0.011 1.12 (1.08-1.16) <.001
Female sex 1.12 (1.09-1.15) <.001 1.18 (1.14-1.21) <.001
No ACS within 30 prior days 2.27 (2.08-2.48) <.001 1.42 (1.28-1.58) <.001
Average days supply, first 90 days of statin era 0.58 (0.57-0.60) <.001 1.63 (1.56-1.70) <.001
Medication (Simvastatin is the comparator for all categories.)        
Atorvastatin 1.13 (1.09-1.18) 0.479 1.07 (0.88-1.29) 0.129
Rosuvastatin 1.06 (1.03-1.10) 0.405 1.08 (0.87-1.33) 0.212
Pravastatin 1.84 (1.23-2.74) 0.003 2.40 (1.52-3.82) <.001
Fluvastatin 1.18 (0.94-1.49) 0.486 1.26 (0.90-1.76) 0.552
Multiple 0.68 (0.62-0.74) <.001 0.73 (0.62-0.86) <.001
aUnits for continuous variable odds ratios: PDC, 0.5; age, 20 years; pills per day, 5; reimbursement per day, $20; copayment per day, $6; average statin days supply, 40;
time from eligibility to index, 520 days; average statin reimbursement, $140, average statin copayment, $50, average statin dose, 30 mg. Abbreviations: PDC, proportion of
days covered; ACS, acute coronary syndrome.
doi: 10.1371/journal.pone.0079611.t002
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PLOS ONE | www.plosone.org 6 November 2013 | Volume 8 | Issue 11 | e79611Figure 3.  Model performance versus time of prediction.  Separate curves are presented for members whose first statin fill was
for 30 days or less (circles), and for members whose first statin fill was for more than 30 days (triangles). For the ≤30 day subset,
performance improves sharply between days 30 and 31, and it improves steadily thereafter. However, for the >30 day subset, (most
of whom had 90-day fills,) performance improves sharply only after day 90. Each Y coordinate expresses the performance of a
model that uses prescription fills from days 1 to X to predict adherence from days X to 365.
doi: 10.1371/journal.pone.0079611.g003
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